Impact of Revisions to Reimbursement Prices and Declines in Selling Prices
First written in FY2016. 28 of 30 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2025: 4 of 11 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「In the healthcare industry in which the Group operates, medical institutions continue to face difficult conditions due not only to the impact of revisions to medical service fees and other factors, but also to rising material costs and the chronic shortage of healthcare professionals.」
The description continues to state that, in addition to the impact of revisions to medical service fees and other factors, rising material costs and shortages of healthcare professionals are contributing to the difficult environment faced by medical institutions. - FY2025RestatedAnnual report
「Reimbursement prices for specified insured medical materials are generally revised once every 2 years. Following these revisions, insurance reimbursement prices have generally been trending downward, and the prices of products sold by medical device distributors to medical institutions, which are linked to those reimbursement prices, have also been trending downward, potentially affecting the performance of the Group.」
The risk of reimbursement price revisions and lower selling prices has been reconfirmed, and measures to improve production efficiency, plan logistics, sell higher-value-added products and prevent unprofitable products from arising have been described. - FY2024-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of reimbursement price revisions and lower selling prices has been reconfirmed through a comprehensive statement that there have been no new developments or material changes. - FY2024-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk of reimbursement price revisions and lower selling prices has been reconfirmed through a comprehensive statement that there have been no material changes. - FY2023-Q3RestatedAnnual report
「In the healthcare industry in which the Group operates, concerns about COVID-19 continue to affect the recovery in the number of surgeries and examinations. The industry is required to respond to the revision of medical service fees in April 2022, while reforms to the healthcare delivery system as part of the social security framework continue, and difficult conditions persist.」
The difficult business environment resulting from concerns about infectious diseases, their impact on the recovery in the number of surgeries and examinations, the April 2022 revision of medical service fees and reforms to the healthcare delivery system continues to be described. - FY2023-Q2RestatedAnnual report
「In the healthcare industry in which the Group operates, concerns about COVID-19 continue, but there have been signs of recovery in the number of surgeries and examinations. At the same time, difficult conditions continue as the industry is required to respond to this year's revision of medical service fees.」
The difficult healthcare environment requiring responses to the revision of medical service fees continues to be described. - FY2023-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk of reimbursement price revisions and lower selling prices has been reconfirmed through a comprehensive statement that there have been no new developments or material changes. - FY2022RestatedAnnual report
「Following these revisions, insurance reimbursement prices have generally been trending downward, and the prices of products sold by medical device distributors to medical institutions, which are linked to those reimbursement prices, have also been trending downward, potentially affecting the performance of the Group. …The Group is focusing on reducing costs by introducing highly production-efficient equipment and continuously improving production technology, controlling selling costs, including logistics planning to contain logistics expenses, and selling higher-value-added products.」
The risks of lower reimbursement and selling prices, and the measures involving production equipment, production technology, logistics planning and higher-value-added products, have been reconfirmed. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of reimbursement price revisions and lower selling prices has been reconfirmed through a comprehensive statement that there have been no material changes. - FY2022-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of reimbursement price revisions and lower selling prices has been reconfirmed through a comprehensive statement that there have been no material changes. - FY2022-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The overall risks associated with existing businesses and other matters have been reconfirmed as involving no material changes. - FY2022-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk of reimbursement price revisions and lower selling prices has been reconfirmed through a comprehensive statement that there have been no material changes. - FY2021RestatedAnnual report
「As a result of these revisions, insurance reimbursement prices have generally been trending downward, and the prices of products sold by medical device distributors to medical institutions, which move in line with them, have also been trending downward, potentially affecting the Group’s performance.」
The risks of lower reimbursement and selling prices continue to be disclosed, with specific measures involving the introduction of production equipment, improvements in production technology, logistics planning and higher-value-added products. - FY2021-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of reimbursement price revisions and lower selling prices has been reconfirmed through a comprehensive statement that there have been no material changes. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of reimbursement price revisions and lower selling prices has been reconfirmed through a comprehensive statement that there have been no material changes. - FY2020WorsenedAnnual report
「As a result of these revisions, insurance reimbursement prices have generally been trending downward, and the prices of products sold by medical device distributors to medical institutions, which move in line with them, have also been trending downward, potentially affecting the Group’s performance.」
The risk of lower reimbursement and selling prices continues. It also indicates an outlook for further intensification of pressure to contain medical costs, pointing to growing pressure from the external environment. - FY2020-Q3RestatedAnnual report
「In the healthcare industry in which the Group operates, population aging and declining birth rates, population decline and the resulting contraction of the labor force are making further improvements in the management of medical institutions and reductions in medical costs important issues, while healthcare system reforms are being pursued to realize the future vision for healthcare and nursing care promoted by the government. The environment surrounding healthcare remains challenging, and related companies continue to face a need to promote efficiency significantly.」
It continues to describe the challenging environment and the need for efficiency against a backdrop of population aging, declining birth rates, the contraction of the labor force due to population decline, reductions in medical costs and healthcare system reforms. - FY2020-Q2RestatedAnnual report
「In the healthcare industry in which the Group operates, population aging and declining birth rates, population decline and the resulting contraction of the labor force are making further improvements in the management of medical institutions and reductions in medical costs important issues, while healthcare system reforms are being pursued to realize the future vision for healthcare and nursing care promoted by the government. The environment surrounding healthcare remains challenging, and related companies continue to face a need to promote efficiency significantly.」
It continues to describe the challenging environment surrounding healthcare and the need for efficiency against a backdrop of population aging, declining birth rates, the contraction of the labor force due to population decline and reductions in medical costs. - FY2020-Q1RestatedAnnual report
「The environment surrounding healthcare remains challenging, and related companies continue to face a need to promote efficiency significantly.」
It continues to describe the challenging environment surrounding healthcare and the need for related companies to improve efficiency. - FY2019-Q3RestatedAnnual report
「Medical service fees were revised last year, and the environment surrounding healthcare remains challenging, while related companies continue to face a need to promote efficiency significantly.」
It continues to describe the challenging environment surrounding healthcare and the need for related companies to improve efficiency following the revision of medical service fees. - FY2019-Q2RestatedAnnual report
「The FY2018 revision of medical service fees was implemented, and the environment surrounding healthcare remains challenging, while related companies continue to face a need to promote efficiency significantly.」
It continues to describe the challenging environment surrounding healthcare and the need for efficiency following the FY2018 revision of medical service fees. The filing does not provide specific changes in reimbursement price figures. - FY2019-Q1RestatedAnnual report
「The FY2018 revision of medical service fees was implemented, and the environment surrounding healthcare remains challenging, while related companies continue to face a need to promote efficiency significantly.」
It continues to describe the challenging environment surrounding healthcare and the need for efficiency following the FY2018 revision of medical service fees. - FY2018RestatedAnnual report
「As a result of these revisions, insurance reimbursement prices have generally been trending downward, and the prices of products sold by medical device distributors to medical institutions, which move in line with them, have also been trending downward. The Group is pursuing cost reductions and improvements in sales efficiency in response to lower selling prices, but if these measures do not produce sufficient results, the Group’s performance may be affected.」
The policy of responding to lower reimbursement and selling prices through cost reductions and improvements in sales efficiency is being continued. - FY2018-Q3RestatedAnnual report
「The environment surrounding healthcare remains challenging, and related companies continue to face a need to promote efficiency significantly.」
It continues to describe the challenging environment surrounding healthcare and the need for related companies to improve efficiency. - FY2018-Q2RestatedAnnual report
「The environment surrounding healthcare remains challenging, and related companies continue to face a need to promote efficiency significantly.」
It continues to describe the challenging environment surrounding healthcare and the need for related companies to improve efficiency. - FY2018-Q1RestatedAnnual report
「The environment surrounding healthcare remains challenging, and related companies continue to face a need to promote efficiency significantly.」
It continues to describe the challenging environment surrounding healthcare and the need for related companies to improve efficiency. - FY2017-Q3RestatedAnnual report
「The FY2016 revision of medical service fees also left the environment challenging, and related companies continue to face a need to promote efficiency significantly.」
It continues to describe the challenging business environment surrounding revisions to medical service fees and the need for efficiency. - FY2017-Q2RestatedAnnual report
「The FY2016 revision of medical service fees also left the environment challenging, and related companies continue to face a need to promote efficiency significantly.」
It continues to describe the challenging business environment surrounding revisions to medical service fees and the need for efficiency across the industry. - FY2017-Q1RestatedAnnual report
「The FY2016 revision of medical service fees also left the environment challenging, and related companies continue to face a need to promote efficiency significantly.」
It continues to describe the challenging environment surrounding revisions to medical service fees and the need for efficiency across the industry. - FY2016First statedAnnual report
「Reimbursement prices for designated medical materials have been revised in stages. As a result, insurance reimbursement prices have generally been trending downward, and the prices of products sold by medical device distributors to medical institutions, which move in line with them, have also been trending downward.」
The Company is pursuing cost reductions and improvements in sales efficiency in response to lower prices, but identifies an impact on performance as a risk if these measures are insufficiently effective.